About Sentien Biotechnologies
Sentien Biotechnologies is a company based in Lexington (United States) founded in 2008 by Biju Parekkadan and Brian Miller. Sentien Biotechnologies has raised $13.05 million across 3 funding rounds from investors including HHS, Portage Biotech and Boehringer Ingelheim Venture Fund. The company has 7 employees as of December 31, 2021. Sentien Biotechnologies operates in a competitive market with competitors including Aclaris Therapeutics, Escient Pharmaceuticals, Nimbus Therapeutics, Alpine Immune Sciences and Septerna, among others.
- Headquarter Lexington, United States
- Employees 7 as on 31 Dec, 2021
- Founders Biju Parekkadan, Brian Miller
-
Sectors
Healthcare
-
Email
Locked
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Sentien Biotechnologies Inc
-
Annual Revenue
Not available
-
Net Profit
Not available
-
EBITDA
Not available
-
Total Equity Funding
$13.05 M (USD)
in 3 rounds
-
Latest Funding Round
$12 M (USD), Series A
Apr 04, 2017
-
Investors
HHS
& 6 more
-
Employee Count
7
as on Dec 31, 2021
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
People of Sentien Biotechnologies
Unlock access to complete
Unlock access to complete
Unlock access to complete
Funding Insights of Sentien Biotechnologies
Sentien Biotechnologies has successfully raised a total of $13.05M across 3 strategic funding rounds. The most recent funding activity was a Series A round of $12 million completed in April 2017. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in Sentien Biotechnologies
Sentien Biotechnologies has secured backing from 7 investors, including venture fund and institutional investors. Prominent investors backing the company include HHS, Portage Biotech and Boehringer Ingelheim Venture Fund.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Healthcare investments are targeted by Boehringer Ingelheim Venture Fund.
|
Locked | Locked | Locked | |
|
Chiesi Ventures is focused on venture capital for rare diseases.
|
Locked | Locked | Locked | |
|
-
|
Locked | Locked | Locked |
Investor details for Sentien Biotechnologies
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Sentien Biotechnologies
Investment portfolio details for Sentien Biotechnologies
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - Sentien Biotechnologies
Detailed financials for Sentien Biotechnologies
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Sentien Biotechnologies Comparisons
Peer comparison for Sentien Biotechnologies
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Sentien Biotechnologies
Sentien Biotechnologies operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Aclaris Therapeutics, Escient Pharmaceuticals, Nimbus Therapeutics, Alpine Immune Sciences and Septerna, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Novel dermatologic therapies are developed for skin conditions.
|
|
| Locked | Locked | Locked |
Small molecule therapeutics for inflammatory diseases are developed.
|
|
| Locked | Locked | Locked |
Targeted therapeutics for cancer, metabolic, and inflammatory diseases are developed.
|
|
| Locked | Locked | Locked |
Developer of immunotherapies to treat cancer and autoimmune disorders
|
|
| Locked | Locked | Locked |
GPCR drug discovery platform is developed for multiple diseases.
|
|
| Locked | Locked | Locked |
Provider of small molecule based drug for inflammatory kidney disease
|
Detailed competitors of Sentien Biotechnologies
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Sentien Biotechnologies
Complete news archive for Sentien Biotechnologies
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Sentien Biotechnologies
Sentien Biotechnologies was founded in 2008 and raised its 1st funding round 2 years after it was founded.
Sentien Biotechnologies is headquartered in Lexington, United States. It is registered at Lexington, Kentucky, United States.
Brian Miller is the current CEO of Sentien Biotechnologies. They have also founded this company.
Sentien Biotechnologies is a funded company, having raised a total of $13.05M across 3 funding rounds to date.
As of Dec 31, 2021, the latest employee count at Sentien Biotechnologies is 7.
Sentien Biotechnologies was founded in 2008 in Lexington, United States, as a pre-clinical regenerative medicine company. Cell-based therapies for acute organ failure are being developed, including proprietary cell compositions. The lead product, Sentinel, is designed to address severe acute kidney injury by supplementing patient blood with mesenchymal stem cell-derived secretions during dialysis. Integration with existing dialysis equipment is incorporated into the device design.
Sentien Biotechnologies's top competitors include Escient Pharmaceuticals, Nimbus Therapeutics and Alpine Immune Sciences.
Sentien Biotechnologies has 7 investors. Key investors include HHS, Portage Biotech, Boehringer Ingelheim Venture Fund, Chiesi Ventures, and MBL Venture Capital.